NCT07520240 is a Phase 1 clinical trial of ITX24-01 in Facet Joint Pain, sponsored by Interventional AnalgesiX Inc..

Who is sponsoring NCT07520240?

NCT07520240 is sponsored by Interventional AnalgesiX Inc..

What drugs are being tested in NCT07520240?

Interventions in NCT07520240: ITX24-01, Normal Saline (0.9% NaCl).

What condition does NCT07520240 study?

NCT07520240 studies Facet Joint Pain.

Is NCT07520240 still recruiting?

NCT07520240 is currently not yet recruiting. Last updated 9 April 2026.

Last reviewed 2026-04-09 · How we verify

NCT07520240

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ITX24-01 in Adult Male and Female Patients With Select Types of Severe Chronic Neck- and Lower Back Pain

Not yet recruiting Phase 1 Last updated 9 April 2026

What this trial tests

Phase 1 trial testing ITX24-01 in Facet Joint Pain in 32 participants. Not yet recruiting.

Timeline

1 June 2026

Primary endpoint
31 January 2027

30 April 2027

Quick facts

Lead sponsor	Interventional AnalgesiX Inc.
Phase	Phase 1
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	32
Start date	1 June 2026
Primary completion	31 January 2027
Estimated completion	30 April 2027
Sites	1 location across Australia

Drugs / interventions tested

ITX24-01
Normal Saline (0.9% NaCl) — full drug profile →

Conditions studied

Facet Joint Pain — all drugs for Facet Joint Pain →

Sponsor

Interventional AnalgesiX Inc.

Who can join

18 and older, any sex, with Facet Joint Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is a single ascending dose (SAD), single-center, randomised, double-blind, placebo-controlled Phase 1b clinical trial designed to evaluate the safety, tolerability, and preliminary analgesic efficacy of ITX24-01 in patients with severe chronic zygapophysial joint pain (facet joint pain). The study consists of three dose escalation cohorts and one extension cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Facet Joint Pain

Currently open trials in the same condition.

NCT05909709 — Dose Escalation Pilot Study to Evaluate the Safety of Alocyte for the Treatment of Facetogenic Back Pain · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07520240 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Interventional AnalgesiX Inc.
Last refreshed: 9 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07520240.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing